SEC EDGARJUN 11 min read$PGEN

Sabzevari Helen sold $520K of PGEN

Sabzevari Helen (President and CEO) sold 119,250 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.52M total) on 2026-05-28.

Original reporting

SEC EDGAR · Sabzevari Helen

Published Jun 1, 2026, 8:25 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jun 1, 2026, 8:38 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PGEN

Neutral

medium confidence

Mentioned

$PGEN

Relevance

7/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PGENNeutralLow

Why it matters

Traders may treat the disclosure as a small sentiment datapoint; without new guidance, trial, or financial results, it typically has limited predictive power.

Market read

Insider selling disclosure can slightly pressure sentiment, but lacks fundamental follow-through in the article.

What to watch

No 10b5-1 plan is cited, but the filing alone does not reveal intent, future trading windows, or whether additional insider sales/buys occurred around the same period.

Relevance 7/10Novelty 6/10Timing: After-hours/next-session read-through from 2026-05-28 sale disclosed on 2026-06-01

Background

The article summarizes a newly filed SEC Form 4 insider transaction for Precigen (PGEN).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PGENNeutralMedium confidence

Context

SEC Form 4 shows CEO Sabzevari Helen sold 119,250 shares of Precigen at $4.36 on 2026-05-28.

Expected impact

Likely limited near-term impact; any move would be sentiment-driven rather than fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying company-specific operational or financial news; also notes no 10b5-1 plan.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector-wide development.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may reflect diversification, liquidity needs, or routine compensation taxes rather than a bearish view, especially since the transaction is disclosed as an open-market sale.

Key entities

issuer
PRECIGEN, INC.
Company whose CEO filed the insider sale disclosure.
insider
Sabzevari Helen
President and CEO who sold shares via open-market sale.

Read at source ← All news

NOV 2

$PGENMedAI 8/10

Precigen Sinks 26% as Inovio Wins FDA Approval for Papzimeos Rival Days Before Earnings

Precigen (PGEN) shares dropped 26% after Inovio (INO) received FDA approval for Voceryq, a rival to Precigen's Papzimeos. Voceryq offers easier dosing, though Papzimeos showed stronger trial results. Precigen reports Q3 earnings on November 4, with analysts expecting $236M in 2026 revenue.

finance.yahoo.com6 min

NOV 2

$PGENHighAI 9/10

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings

Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).

finance.yahoo.com2 min

OCT 30

$INOHighAI 9/10

FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours

FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.

finance.biggo.com3 min

SEP 29

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

insidermonkey.com3 min

SEP 21

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

prnewswire.com2 min

AUG 21

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min